Published by Josh White on 11th October 2023
(Sharecast News) - Faron Pharmaceuticals announced encouraging updated data from its ongoing phase one and two 'BEXMAB' study into relapsed or refractory (r/r) acute myeloid leukaemia (AML) and myelodysplastic syndromes (MDS) treatments on Wednesday.
URL: http://www.digitallook.com/dl/news/story/33830464/...